Toby M Maher,1 Oliver Distler,2 Yannick Allanore,3 Takashi Ogura,4 John Varga,5 Serena Vettori,6 Bruno Crestani,7 Ute von Wangenheim,8 Manuel Quaresma,9 Margarida Alves,9 Susanne Stowasser,9 Shervin Assassi10 on behalf of the SENSCIS trial investigators
1National Heart and Lung Institute, Imperial College London and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK; 2Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland; 3Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France; 4Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Centre, Yokohama, Japan; 5Northwestern Scleroderma, Feinberg School of Medicine, Chicago, Illinois, USA; 6Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy; 7Hôpital Bichat, Pneumologie, Paris, France; 8Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; 9Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 10Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA
Introduction
- ILD is the leading cause of death related to systemic sclerosis (SSc).1
- Decline in forced vital capacity (FVC) in subjects with SSc-ILD is associated with mortality.2,3
- The primary analysis of the randomized, placebo-controlled SENSCIS trial showed that in subjects with SSc-ILD, treatment with nintedanib was associated with a significant reduction in the rate of decline in FVC (mL/year) over 52 weeks.4